Feature | November 07, 2012

Kona Medical Announces Initiation of WAVE I Study of Renal Denervation Therapy for Hypertension

Kona Surround Sound Technology utilizes externally-delivered ultrasound to treat drug-resistant hypertension

November 7, 2012 — Kona Medical Inc. announced the initiation of the first clinical study of its device therapy for drug-resistant hypertension. The company is sponsoring the WAVE I clinical study to evaluate the safety and efficacy of its novel technology, and is now enrolling subjects at St. Vincent’s Hospital in Melbourne, Australia, under the direction of primary investigator Robert Whitbourn, M.D. The study design and initial results of WAVE I were presented on behalf of the investigators by Todd Brinton, M.D., at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

The Kona Surround Sound system utilizes focused ultrasound, delivered from outside the body, to treat the nerves leading to and from the kidney. The therapy of renal denervation has been shown in other studies to lead to significant and lasting reductions in high blood pressure. Unlike other renal denervation methods, which rely on a catheter emitting therapeutic energy through the wall of the renal artery to affect the renal nerves, Kona’s Surround Sound technology uses a novel method of treating the nerves from outside the patient. A transducer positioned outside the body delivers targeted ultrasound energy that “surrounds” the artery and treats the nerves located in the vicinity of the vessel. By creating a focused energy field around the outside of the artery, the Kona system may result in a more complete and effective ablation in a way that does not impact the walls of the artery.

“Renal denervation is becoming one of the fastest-growing interventional therapies,” said Whitbourn. “The Kona system has the potential to further improve clinical results, and may also lead to improved access to renal denervation therapy. We are pleased to be participating in the evaluation of the Kona system and anticipate reporting complete study results next spring.”

“Initiation of the WAVE I study is an important milestone in the development of therapies for hypertension,” added Michael Gertner, M.D., founder and CEO of Kona Medical. “Ultrasound has inherent advantages as an energy source for ablation, and we believe that external delivery of ultrasound energy better addresses the variability of the location of renal nerves and may lead to better outcomes. Importantly, focused external ultrasound also can enable a system that is entirely noninvasive. This could greatly expand access to renal denervation therapy, and would offer a more patient-friendly alternative for the tens of millions of people who suffer from drug-resistant hypertension.”

Kona Medical’s technology is investigational and is not yet for sale or approved in the United States.

For more information: www.konamedical.com

Related Content

Xarelto, PMSS, XANTUS, ESC 2015, major bleeding, non-valvular atrial fibrillation, NVAF
News | Antiplatelet and Anticoagulation Therapies| September 04, 2015
Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from PMSS and XANTUS, real-...
ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

Feature | Stents Bioresorbable| September 04, 2015
A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard metal among patients...
CUPID 2, gene transfer therapy, heart failure patients, no benefit, ESC 2015, SERCA2a
News | Stem Cell Therapies| September 04, 2015
Gene transfer therapy to correct an enzyme abnormality involved in myocardial contraction and relaxation did not...
News | Cardiac Resynchronization Therapy Devices (CRT)| September 03, 2015
Sorin Group announced the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe.
CeRtiTuDe cohort study, cardiac resynchronization therapy, CRT-D, CRT-P, ESC 2015
News | Cardiac Resynchronization Therapy Devices (CRT)| September 03, 2015
Most patients with a cardiac resynchronization therapy (CRT) pacemaker would not benefit from the addition of a...
FFR-CT, HeartFlow, PLATFORM trial, ESC 2015, ICA, fractional flow reserve, computed tomography

Image courtesy of HeartFlow Inc.

Feature | FFR Catheters| September 03, 2015
Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for...
News | Structural Heart| September 02, 2015
An investigational material known as Bioabsorbable Cardiac Matrix (BCM), designed to prevent cardiac remodeling in...
acute ischemic stroke, larger thrombi retrieval, improved neurological recovery, ESC 2015, MR CLEAN trial, sub-study
Feature | Thrombectomy Devices| September 02, 2015
Retrieval of larger thrombi during intra-arterial treatment (IAT) is associated with improved neurological recovery...
DOPPLER-CIP trial, ESC 2015, heart failure, predictor, small left ventricle, University of Leuven
Feature | Heart Failure| September 02, 2015
Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small left ventricle with...
Medtronic, OPTILINK, OptiVol, ICD, pulmonary congestion, ESC 2015
Feature | Heart Failure| September 01, 2015
Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with...
Overlay Init